Effects of Early Thyroxine Treatment on Development and Growth at Age 10.7 Years: Follow-Up of a Randomized Placebo-Controlled Trial in Children With Down's Syndrome
- 1 December 2014
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (12), E2722-E2729
- https://doi.org/10.1210/jc.2014-2849
Abstract
Context: In 2-year-old children with Down's syndrome (DS), early T-4 treatment was found to result in slightly better motor development and growth. Objectives: This study sought to determine long-term effects of early T-4 treatment on development and growth in children with DS with either an elevated or normal neonatal TSH concentration. Design: Patients received a single follow-up visit 8.7 years after a randomized placebo-controlled trial (RCT) comparing T-4 and placebo treatment during the first 2 years of life. Setting: Dutch Academic Hospital. Participants: All children who completed the RCT(N = 181, of 196 randomly assigned children) were invited for the follow-up study. A total of 123 participants enrolled, at a mean age of 10.7 years. Interventions: T-4 or placebo treatment from the neonatal period until 2 years. Main Outcome Measures: Primary: mental and motor development. Secondary: communication skills, fine-motor coordination, height, weight, and head circumference (HC). Outcomes were compared between T-4- and placebo-treated children, and between treatment groups with either a normal (5 mIU/L) TSH concentration at original trial entry. Results: Mental or motor development, communication skills, or fine-motor coordination did not differ between T-4-(N = 64) and placebo-treated children (N = 59). T-4-treated children had a larger HC (50.4 vs 49.8 cm, P = .04) and tended to be taller (133.2 vs 131.1 cm, P = .06). These differences were somewhat greater in children with TSH <5 mIU/L (HC: T-4, 50.5 vs placebo, 49.7 cm; P = .01; height: T-4, 133.8 vs placebo, 130.8 cm; P = .02), but were not found in children with TSH <5 mIU/L (HC: T-4, 50.1 vs placebo, 50.0 cm; P = .75; height: T-4, 132.1 vs placebo, 131.6 cm; P = .22). Conclusions: Early T-4 treatment of children with DS does not seem to benefit mental or motor development later in life. However, the positive effect on growth is still measurable, especially in children with an elevated plasma TSH concentration in the neonatal period.Keywords
This publication has 12 references indexed in Scilit:
- ENDOCRINE DISORDERS IN CHILDHOOD AND ADOLESCENCE: Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a reviewActa Endocrinologica, 2013
- Down Syndrome and Thyroid FunctionEndocrinology and Metabolism Clinics of North America, 2012
- Subclinical hypothyroidism in children: natural history and when to treatJournal of Clinical Research in Pediatric Endocrinology, 2012
- Euthyroid Submedian Free T4 and Subclinical Hypothyroidism May Have a Detrimental Clinical Effect in Down SyndromeHormone Research in Paediatrics, 2012
- Hyperthyrotropinaemia in untreated subjects with down's syndrome aged 6 months to 64 years: a comparative analysisArchives of Disease in Childhood, 2012
- Development and validation of the Arizona Cognitive Test Battery for Down syndromeJournal of Neurodevelopmental Disorders, 2010
- Variability of cognitive development in children with Down syndrome: Relevance of good reasons for using the cluster procedureResearch in Developmental Disabilities, 2009
- Intellectual and Motor Development of Young Adults with Congenital Hypothyroidism Diagnosed by Neonatal ScreeningJournal of Clinical Endocrinology & Metabolism, 2006
- The Effect of Thyroxine Treatment Started in the Neonatal Period on Development and Growth of Two-Year-Old Down Syndrome Children: A Randomized Clinical TrialJournal of Clinical Endocrinology & Metabolism, 2005
- Timing of Thyroid Hormone Action in the Developing Brain: Clinical Observations and Experimental FindingsJournal of Neuroendocrinology, 2004